Status:
COMPLETED
Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Kidney Failure, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this clinical study is to compare the effects of Genz-644470 with the effects of placebo and sevelamer carbonate (Renvela®) on the reduction of serum phosphorus in hyperphosphatemic chr...
Eligibility Criteria
Inclusion
- Serum phosphate level greater than (\>) 5.5 milligram per deciliter (mg/dL) (1.78 millimole per liter \[mmol/L\]) after discontinuation of current phosphate binder therapy
- Men or women 18 years or older
Exclusion
- Have active dysphagia or swallowing disorder or a predisposition to or current bowel obstruction, ileus, or severe gastrointestinal motility disorders including severe constipation
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
349 Patients enrolled
Trial Details
Trial ID
NCT00853242
Start Date
February 1 2009
End Date
August 1 2009
Last Update
May 1 2015
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
Alexander City, Alabama, United States
2
Birmingham, Alabama, United States
3
Hot Springs, Arkansas, United States
4
Bakersfield, California, United States